Modified and chimeric cytokines have been developed to aid in the recovery of hematopoietic precursor cells after myeloablative chemotherapy. The interleukin-3 (IL-3) receptor agonist, daniplestim, binds to the IL-3 receptor-␣ subunit with 60-fold greater affinity and induces cell proliferation and colony-forming unit formation 10-to 22-fold better than native IL-3. A chimeric cytokine, myelopoietin-1, composed of daniplestim and a G-CSF receptor agonist binds both the IL-3 and G-CSF receptors. While the in vivo effects of daniplestim and myelopoietin-1 are well described, the mechanisms by which they stimulate growth are not well understood. We have investigated the effects of daniplestim and myelopoietin-1 on the prevention of apoptosis in two human hematopoietic cell lines, OCI-AML.5 and AML 193. Daniplestim and myelopoietin-1 prevented apoptosis to a greater degree than native recombinant IL-3 or G-CSF as determined by annexin V/propidium iodide binding and TUNEL assays. Daniplestim and myelopoietin-1 promoted the maintenance of the mitochondrial membrane potential better than native IL-3 or G-CSF. These cytokines promoted a lower redox potential as higher levels of free radicals were detected after cytokine treatment than in cytokine-deprived cells implying increased respiration. These results indicate that daniplestim and myelopoietin-1 are able to prevent apoptosis in hematopoietic cells more effectively than native IL-3 and G-CSF. These effects of daniplestim and myelopoietin-1 may contribute to their effective ability to repopulate hematopoietic precursor cells after chemotherapy. Leukemia (2001Leukemia ( ) 15, 1203Leukemia ( -1216 
Introduction
Apoptosis is an intrinsic mechanism of cell death in which a variety of stimuli can activate specific cellular factors to effectively 'dismantle' the cell and facilitate its removal from a population without adversely affecting neighboring cells. Apoptosis is a normal process of cell elimination that occurs during development, homeostasis, and self-reacting immune cell depletion. [1] [2] [3] [4] [5] [6] [7] [8] Apoptosis also plays a role in eliminating cells exposed to environmental stress factors such as growth factor withdrawal, irradiation, ischemia, and viral infection. Dysregulation of apoptosis can lead to immortalization of cells and cancer. [1] [2] [3] [4] [5] [6] [7] [8] In general, morphological changes observed in cells undergoing apoptosis include the loss of cytoplasmic volume and shrinkage, whereas cells dying by necrosis tend to swell. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Chromatin condenses progressively, forming small, diffuse foci that may fuse and marginate against the nuclear membrane, and eventually collapse into a round, dense structure. The nucleus often breaks up into membrane-bound bodies, which may or may not contain chromatin. The cell itself may fissure into multiple membrane-bound apoptotic bodies containing nuclear fragments, or shrink into a single, dense and round apoptotic body. Biochemical changes associated with apoptosis include specific patterns of DNA, ribosomal RNA and protein cleavage, increased intracellular Ca ++ , loss of mitochondrial transmembrane potential (), release of cytochrome c (cyto c) from mitochondria, change in the redox status of the cells, and externalization of phosphatidylserine (PS) from the inner plasma membrane. The most commonly accepted biochemical indicator of apoptosis is the cleavage of DNA into oligonucleosomal-sized fragments. 8, 9 Most morphological changes in apoptosis are consequences of caspase activation. Apoptosis has been referred to as cell death with caspase activation. 4, 5 Hematopoietic cells continue to undergo apoptosis after myeloablative therapy, thus there is a need to be able to repopulate the hematopoietic cell compartments after chemotherapy and many other leukemia therapies.
Cytokine stimulation suppresses apoptosis via different mechanisms. 1, [10] [11] [12] [13] [14] [15] [16] The carboxyl-region of the IL-3 receptor beta (R␤ c ) chain has been associated with the IL-3-mediated prevention of apoptosis. Dimerization of the IL-3 receptor by IL-3 creates a docking site for phosphatidylinositol 3-kinase (PI3K) which then phosphorylates membrane lipids which result in the recruitment of the serine/threonine kinase Akt (aka protein kinase B, PKB) by its pleckstrin homology domain. Moreover, the phospholipids modified by PI3K also activate the PDK1 and PDK2 serine/threonine kinases which phosphorylate Akt on two different residues leading to its activation. Activated Akt can phosphorylate many downstream proteins including: Bad, glycogen synthase kinase-3 ␣/␤ (GSK-3␣/␤) Gsk-2, forkhead transcription factors (FKHR), and caspase-9 and IK. 1, 10, [14] [15] [16] Once Bad is phosphorylated it is bound by 14-3-3 proteins which sequester Bad in the cytoplasm away from its normal site of action the mitochondrion. 14, 15 The unphosphorylated form of Bad normally forms heterodimers with anti-apoptotic factors, such as Bcl-x L or Bad, to induce cell death. 14, 15 Phosphorylation of Bad induced by IL-3 stimulation, releases Bad from Bcl-x L or Bad which can then form heteroduplexes with Bax and result in the prevention of apoptosis. IL-3 can also activate the Ras/Raf/MEK/ERK pathway. ERK2 and p90
Rsk can also phosphorylate Bad, 10, 15 indicating that the Raf/MEK/ERK and PI3K/Akt pathways have converging effects on the regulation of apoptosis. IL-3 also activates the Jak/STAT pathway which can control gene expression. 1 Jak kinases can regulate Raf activity and full activation of Jak activity is fine-tuned by ERK. 1 STAT transcription factors induce the transcription of the antiapoptotic Bcl-X L gene. Clearly cytokines induce multiple pathways which cross-talk and regulate apoptosis. Rather than being linear, these pathways are often more web-like in design.
Daniplestim, an engineered IL-3 receptor agonist, binds to the IL-3 receptor ␣ subunit with 60-fold greater affinity and to the IL-3 receptor ␣/␤ complex with 20-fold greater affinity Leukemia than native IL-3. [17] [18] [19] [20] [21] [22] In colony-forming unit (CFU) assays using human bone marrow-derived CD34 + cells, daniplestim demonstrated 22-fold greater potency than native IL-3. The in vivo utility of daniplestim was evident in rhesus mobilization and myelosuppression models. 23, 24 Myelopoietin-1 belongs to a family of engineered chimeric molecules, which bind and activate both human IL-3 and G-CSF receptors. 25, 26 In CFU assays, myelopoietins demonstrate greater potency than the co-addition of native IL-3 and G-CSF. 24 The in vitro proliferative activity of myelopoietins correlate with their signaling potential for activation of JAK-2 and STAT proteins. Myelopoietin-1-induced phosphorylation of JAK-2, STAT-3 and STAT-5 was more pronounced and longer in duration suggesting that the chimeric molecule may alter the magnitude and kinetics of signaling events. In the rhesus myelosuppression model, myelopoietins were more effective in repopulating specific hematopoietic cell compartments than a combination of native IL-3 and G-CSF. 24, 27 The following study was undertaken to determine whether the enhanced ability of daniplestim and myelopoietin-1 to repopulate hematopoietic precursor cells could be attributed in part to their abilities to suppress apoptosis.
Materials and methods

Cell lines and growth factors
Human cytokine-responsive OCI-AML.5 and AML 193 cells 28 were obtained from the German collection of microorganisms and cell cultures (Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ, Braunschweig, Germany). OCI-AML.5 cells were maintained in a humidified 5% CO 2 incubator with ␣-MEM (Life Technologies, Gaithersburg, MD, USA) supplemented with 20% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA), penicillin/ streptomycin/L-glutamine (antibiotics) (Life Technologies), 5 × 10 −5 M 2-mercaptoethanol (2-ME; Sigma, St Louis, MO, USA), 2 ng/ml each of rG-CSF, rIL-3 and rFLT-3 ligand (FL). AML 193 cells were maintained in the same incubator in Iscove's MEM containing 2 ng/ml GM-CSF, 10% FBS, antibiotics, and 2-ME as described above. Recombinant IL-3 and GM-CSF purchased from R & D (Minneapolis, MN, USA). Recombinant G-CSF, FL, daniplestim, myelopoietin-1 were prepared at Pharmacia Corporation (St Louis, MO, USA). Cytokine concentrations are given in either ng/ml or pg/ml, all agonists had molecular weights which varied within a two-fold range. In many experiments, cytokines were used at saturating levels (2 ng/ml) to ensure that the full protective effects of the particular cytokine were observed. The levels of [ 3 H]-thymidine incorporation and the protective effects as measured by annexin V, TUNEL assays, DNA fragmentation assays did not differ whether 1000 or 2000 pg/ml of the particular native or chimeric cytokine were used. 
H]-thymidine incorporation
Cell proliferation assays were performed in 96-well flat bottom plates (Corning, Corning, NY, USA) with 10 4 cells/well that were incubated for the various time periods in the presence of the indicated cytokines. Each condition was assayed in triplicate. [29] [30] [31] After 3 days of culture, 10 l of [ 3 H]-thymidine (6.7 Ci/mmol, (10 mCi/ml); New England Nuclear (NEN), Boston, MA, USA) was added to each well, and the cells were harvested 5 h later with an automated Tomtec Mac II (Orange, NJ, USA) 96-well plate harvester and counted on a 1450 Microbeta plate counter (Wallac, Gaithersburg, MD, USA) as described. 6, [32] [33] [34] Detection of apoptosis by acridine orange-ethidium bromide staining
The cells were grown in the presence and absence of the indicated cytokines (each at 2 ng/ml) for 2 days and then harvested by centrifugation at 400 g for 10 min. The cells were then stained with ethidium bromide (4 g/ml)/acridine orange (4 g/ml) (Sigma) for 30 min and apoptotic cells were visualized by fluorescent microscopy.
Isolation of low molecular weight DNAs for DNA fragmentation assays
Ten million cells (4 × 10 5 /ml) were grown in the different conditions for 2 days. The cells were pelleted by centrifugation, DNAs isolated, quantitated and DNA fragmentation gels run as previously described. 34, 35 Apoptosis assays using annexin V/Propidium iodide Cells were grown with the indicated supplements in T25 tissue culture flasks (Corning, Corning, NY, USA) in 10 ml of medium. Cells (ෂ1 × 10 6 ) were harvested and washed twice in 1 ml of phosphate-buffered saline (PBS) containing Ca 2+ and Mg +2 as described. 36, 37 The cells were then resuspended in 100 l of (1 g/ml annexin V-FITC; (Roche Diagnostics, Indianapolis, IN, USA), in binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl 2 ) and incubated in the dark at room temperature for 15 min. Following the incubation, the cells were washed once in PBS as before. After removing the PBS, the cells were resuspended in 100 l of propidium iodide (PI) solution (Roche Diagnostics; 10 g/ml in binding buffer) and incubated in the dark for 15 min at room temperature. Once the incubation was complete, 0.7 ml of binding buffer was added directly to the samples which were then analyzed using a FACScan. Prior to treating with annexin or PI, in some cases, [ 3 H]-thymidine incorporation was measured on some of the cells by removing 3 × 100 l aliquots of the cells and plating them in triplicate wells of 96-well plates and counted as described above.
Detection of apoptosis by TUNEL
The TUNEL (terminal deoxynucleotidyl transferase (TdT) mediated dUTP nick translation end labeling) method was also used to detect apoptosis. Exogenous TdT can catalyze a template-independent addition of bromodeoxyuridine triphosphates (Br-dUTP, BrDU) to the free 3Ј-hydroxyl ends of double or single stranded DNA fragments. After the incorporation, the labeled BrDU was identified by a FITC-conjugated anti-BrDU antibody and quantitated by flow cytometry. The BioSource International APO-BRDU kit (Camarillo, CA, USA) was used for TUNEL assays. Previous studies with CD34 + cells have validated the combination of annexin V binding, DNA fragmentation, and TUNEL assays to monitor the induction of apoptosis due to either cytokine-withdrawal or treatment with differentiation-inducing drugs.
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Mitochondrial membrane potential of cytokine-treated cells
The mitochondrial membrane potential of the OCI-AML.5 cells treated under the different conditions was examined using the fluorescent lipophilic cationic dye Rhodamine-123 (Rh-123; Sigma). After collection of the cells by centrifugation at 400 g for 10 min, the cells were resuspended in 1 ml of PBS. Rh-123 was added to the cells to a concentration of 2 M. PI was added to a concentration of 50 M. The cells were then incubated at 37°C in a 5% CO 2 incubator for 20 min. Then the cells were collected by centrifugation and washed with PBS twice. Rh-123 and PI fluorescence were then analyzed by flow cytometry.
Flow cytometric analysis of intracellular peroxide levels
Intracellular peroxide levels were measured as previously described 42 using 2Ј7Ј-dichlorofluorescein diacetate (DCFH-DA; Sigma). The cells were grown in ␣MEM medium with the indicated cytokines for 48 hrs. The cells were then pelleted by centrifugation and resuspended in ␣MEM containing 5 M of DCFH-DA. The cells were then incubated for an additional 15 min at 37°C and placed on ice. The fluorescence intensity of the cells was then measured by flow cytometry.
Results
Effects of daniplestim and myelopoietin-1 on [
H]-thymidine incorporation in OCI-AML.5 cells
The OCI-AML.5 cell line is a cytokine-responsive acute myelogenous leukemia line (AML) which responds to multiple cytokines including IL-3, G-CSF and FL. 28 To determine the ability of native IL-3, daniplestim and myelopoietin-1 to promote [ In those cases where the error bars are not visible, the standard deviation is contained within the size of the symbol. These experiments were performed three times with similar results.
Analysis of apoptotic cells by staining with acridine orange and ethidium bromide
To visualize the effects of daniplestim and myelopoietin-1 on the prevention of apoptosis, the OCI-AML.5 cells were grown in the presence of the indicated cytokines for 2 days and then stained with ethidium bromide and acridine orange. Ethidium bromide and acridine orange are both nucleic acid stains used to visualize DNA or RNA. During apoptosis when DNA is condensed, staining with either ethidium bromide or acridine orange becomes brighter and there is a loss of diffuse heterogeneity as the DNA becomes more tightly condensed. Acridine orange stains all cellular nucleic acid green, but ethidium bromide only enters cells in which the plasma membrane has become permeable so it only stains the nucleic acids of dead cells. Therefore, in the ethidium bromide/acridine orange assay, four cell types can be distinguished as dead or alive by color (orange or green, respectively) and apoptotic or nonapoptotic cells based on chromatin condensation. As observed in Figure 2 , when the OCI-AML.5 cells were grown in the presence of no cytokine for 2 days, bright orange cells were observed indicating late apoptotic dead cells. Treatment of the cells with daniplestim + G-CSF also resulted in fewer dead cells as compared with no cytokine, G-CSF or IL-3-treated cells (panel e). There were routinely fewer dead cells when the cells were cultured with myelopoietin-1 (panel f). Thus, by fluorescence microscopy, the anti-apoptotic effects of daniplestim and myelopoietin-1 on the prevention of apoptosis could be readily visualized.
Ability of daniplestim and myelopoietin-1 to prevent apoptosis
Annexin V binding allows detection of phosphatidylserine (PS), a negatively charged phospholipid, in the cell mem- brane. Normally, PS is restricted to the inner surface of the plasma membrane and is not accessible to extracellular annexin V. Early in apoptosis, PS is externalized to the outer plasma membrane and is an early marker of apoptosis. 1, 37 Propidium iodide (PI) like ethidium bromide, is a nucleic acid stain that cannot enter cells unless the plasma membrane is permeabilized. Simultaneous staining with annexin V and PI allows quantitation of apoptotic cells characterized by externalized PS and an intact plasma membrane.
The ability of the different cytokines to prevent PS exposure on the outer leaflet of the cell membranes was measured by the annexin V/PI binding assay. OCI-AML.5 cells were grown for different time periods in the presence of no cytokine, daniplestim, G-CSF, daniplestim plus G-CSF, and different concentrations of IL-3 and myelopoietin-1 for varying periods of time. Every 24 h, a 3 ml aliquot containing approximately 1 × 10 6 cells was removed from each culture and stained with FITCconjugated annexin V and PI, and the percentages of the early apoptotic, late apoptotic/necrotic, alive and dead cells were determined by flow cytometric analysis. Representative data from an annexin V/PI experiment on cells cultured for 3 days in the presence of the indicated cytokines is presented in Figure 3 .
Culture of the cells in the absence of any cytokine for 3 days resulted in only 31% of the cells being identified as alive, non-apoptotic (annexin-negative, PI-negative) as determined by the annexin V/PI assay (panel a). Thirty-nine percent of the cells in this culture were in the early phase of apoptosis (annexin-positive, PI-negative), 21% in the late apoptotic/ necrotic phase (annexin-positive, PI-positive) and 9% of the cells were registered as dead cells (annexin-negative, PI-positive cells). Interestingly, when the cells were cultured in daniplestim (panel b) for 3 days, 82% of the cells were viable, and only 11% were early apoptotic, 5% late apoptotic and 3% dead. When the cells were cultured in the presence of G-CSF (panel c), the overall number of dead cells and the percentage of apoptotic cells increased with 58% viable, 24% early apoptotic, 14% late apoptotic and 4% dead. Treatment of the cells with the co-addition of daniplestim and G-CSF (each at 2000 pg/ml, panel d) resulted in 85% viable, 9% early apoptotic, Figure 1 . Flow cytometric coordinates were first determined using unstained live cells. In cases where there were two dyes used, controls of each separately stained sample were used to obtain the proper settings. For example, for annexin V/PI, three controls were used. Unstained live cells, annexin V stained cells only (apoptotic cells were used for this) and PI stained cells only, these cells were permeablized by ethanol treatment. These experiments were performed four times with similar results. The axes in this figure are in a log 10 :log 10 scale. 4% late apoptotic/necrotic and 2% dead cells. Co-addition experiments were also performed with concentrations of daniplestim and G-CSF at 1000 pg/ml each and similar results were observed (data not presented). Thus, annexin V/PI binding demonstrated that the anti-apoptotic effects of these cytokines fell into the following order with daniplestim + G-CSF Ͼ daniplestim Ͼ IL-3 Ͼ G-CSF.
The effects of IL-3 on the prevention of apoptosis was examined in a dose-response experiment. Doses of IL-3 ranging from 400 (panel f) to 2000 (panel e) pg/ml suppressed apoptosis in the OCI-AML.5 cell line, whereas lower doses (200 and 40, panels g and h) exhibited lower ability to prevent apoptosis. These data suggested IL-3 prevented apoptosis in a dose-dependent mechanism. The entire titration results are presented in Table 1 .
To determine whether myelopoietin-1 would prevent apoptosis as well as the IL-3 or G-CSF, a series of dose response experiments were performed. myelopoietin-1 (panel i) prevented apoptosis better than native IL-3 (panel e) or G-CSF (panel c) at the same concentration of each. Titration experiments indicated that myelopoietin-1 prevented apoptosis at 10-fold lower concentrations than native IL-3 as the same degree of protection from apoptosis was observed at 40 pg/ml of myelopoietin-1 vs 400 pg/ml of native IL-3 ( Figure 3 , Table 1 ). The data obtained on the different days of treatment and various concentrations of cytokines are presented in Table 1 . On day 1, no significant differences were observed in the percentages of the live, dead and apoptotic cells in the cultures containing any of the cytokines, while the no cytokine control contained fewer live cells. Some differences were apparent by day 2, but by day 3, distinct differences were noted among various cytokines in their ability to prevent apoptosis.
A graphical representation of the data obtained at a concentration of 2000 pg/ml of each cytokine is presented in Figure  4 . In this time course experiment, the effects of cytokine deprivation were more evident, as initially approximately 75% of the cells treated with no cytokine were viable on day 1, and this percentage dropped to around 26% after 3 days of cytokine deprivation (panel a). Likewise, the percentage of early apoptotic cells started at 3.6% after 1 day and increased to approximately 35% after 3 days of cytokine deprivation. The percentage of viable cells treated with 2000 pg/ml of IL-3, started at 85% and dropped to 77% after 3 days in culture (panel b). G-CSF exhibited less protective effects from apoptosis as the percentage of viable cells at day 1 was approximately 87% but dropped to 56% after 3 days in culture (panel c). Approximately 90% of the daniplestim-(panel d) and myelopoietin-1 (panel f)-treated cells were viable on day 1 and by day 3 82% of the daniplestim-treated and 86% of myelopoietin-1-treated cells were viable. When the cells were treated with the co-addition of daniplestim and G-CSF, a similar protective effect on viability was observed as 90% of the cells were viable at day 1 and 86% viable at day 3 (panel e). Thus while a decrease in the viability of the IL-3 and G-CSF-treated cells was observed in these time course experiments, a similar decrease was not observed in myelopoietin-1 and daniplestim + G-CSF-treated cells.
A second series of time course and dose-response experiments were performed with a different range of doses of daniplestim, IL-3 and G-CSF (Table 2 ). These data are not included in Table 1 as the experiments were performed with a different concentration of the cytokines and were done on different days. In these other experiments, daniplestim was better in suppressing apoptosis than native IL-3 as the protective effects
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Figure 4
Time course induction of apoptosis as determined by annexin V binding in OCI AML cells. These cells were cultured with the indicated cytokines at 2000 pg/ml. An aliquot of cells was removed each day for 3 days. This is the same set of cells that [ 3 H]-thymidine incorporation was performed on in Figure 1 and the flow cytometric data presented in Figure 3 and Table 1 of daniplestim were observed at 2 pg/ml while the protective effects of native IL-3 were observed at 200 pg/ml. At doses of 2000 pg/ml, native IL-3 was more effective in preventing apoptosis than G-CSF after 3 days of culture.
These experiments indicated that myelopoietin-1 and daniplestim were better at preventing apoptosis in OCI-AML.5 cells than either native IL-3 or G-CSF. However, native IL-3 and G-CSF also prevented apoptosis in these cells as less apoptosis was observed in the IL-3 and G-CSF-treated cells than when the cells were deprived of cytokine. Importantly, the level prevention of apoptosis by myelopoietin-1 followed the dominant properties of daniplestim, as less apoptosis was observed in myelopoietin-1-treated cells than after culture with G-CSF.
The abilities of daniplestim and myelopoietin-1 to prevent apoptosis in another human hematopoietic cell line were determined to ensure that these apoptosis suppressing effects were not limited to a single cell line (Table 3) . Treatment of the AML 193 cells with daniplestim or myelopoietin-1 prevented apoptosis as well as GM-CSF, the cytokine in which this cell line is normally maintained. Moreover, as in OCI-AML.5 cells, the protective effects of myelopoietin-1 followed the dominant effects of daniplestim and not G-CSF. Treatment of the cells with the co-addition of daniplestim and G-CSF (each at either 2000 pg/ml or 1000 pg/ml) resulted in the prevention of apoptosis to a similar level as observed with myelopoietin-1 (Table 3 and data not presented). Thus daniplestim and myelopoietin-1 prevented the induction of apoptosis in two human hematopoietic cell lines as well as, if not better than the native cytokines. 
Figure 5
Apoptosis as detected by TUNEL. The TUNEL assay was performed to determine the percentage of the OCI-AML.5 cells that were apoptotic. Cells were grown in the indicated conditions for two days and then the TUNEL assay was performed. Panels (a) no cytokine, (b) 2000 pg/ml IL-3, (c) 2000 pg/ml G-CSF, (d) 2000 pg/ml daniplestim, (e) 2000 pg/ml daniplestim + 2000 pg/ml G-CSF and (f) 2000 pg/ml myelopoietin-1. The controls used to set coordinates for the TUNEL assay were unstained live cells, TUNEL-stained apoptotic cells generated by depriving OCI-AML.5 cells of cytokine for 2 days and TUNEL-stained live cells. These experiments were performed three times with similar results.
TUNEL analysis of apoptotic cells
An enzymatic marker of the later events of apoptosis is the TUNEL assay which measures incorporation of modified nucleotides at the ends of internucleosomal DNA fragments created during fragmentation of DNA during apoptosis. OCI-AML.5 cells were cultured in the presence of the indicated cytokines: IL-3, daniplestim or myelopoietin-1 for 2 days. The cells were isolated and then the TUNEL assay was performed. Treatment of the cells with no cytokine resulted in approximately 25% of the cells being TUNEL positive as determined by the shift in fluorescence ( Figure 5, panel a) . IL-3 and G-CSF had protective effects on DNA fragmentation as 8.5 and 7% of the cells were TUNEL positive (panels b and c). Moreover, when the cells were treated with daniplestim, approximately only 3.8% of the cells registered as TUNEL positive (panel d). When the cells were treated with a combination of daniplestim and G-CSF or myelopoietin-1, about 3% of the cells were TUNEL-positive cells (panels e and f). Thus, the protective, anti-apoptotic effects of daniplestim + G-CSF and myelopoietin-1 on the prevention of apoptosis were also observed by TUNEL analysis and the level of protection observed in this assay was similar to that observed previously in the annexin/PI assays.
Daniplestim and myelopoietin-1 prevent apoptosis as measured by DNA laddering
To determine whether IL-3, daniplestim and myelopoietin-1 inhibited late events associated with apoptosis, DNA fragmentation gels were run on DNAs isolated from OCI-AML.5 cells cultured with the indicated cytokines ( Figure 6 ). This technique measures late aspects of apoptosis when the caspases and DNases have been activated and cleavage of chromatin Apoptosis as detected by DNA fragmentation. OCI-AML.5 cells were grown with the indicated conditions for 2 days and then the cells were lysed and low molecular DNAs were isolated. DNAs from the respective samples were then resolved by agarose gel electrophoresis. The concentrations of the cytokines supplemented to the medium were: 2000 pg/ml G-CSF, 2000 pg/ml daniplestim, 2000 pg/ml daniplestim + 2000 pg/ml G-CSF, and 2000 pg/ml myelopoietin-1. These experiments were performed three times with similar results.
into nucleosomal fragments has occurred. Addition of no cytokine resulted in the generation of an apoptotic DNA fragment ladder (lane 1). In contrast, treatment of the cells with a combination of G-CSF and daniplestim (lane 2), G-CSF (lane 3), daniplestim (lane 4), or myelopoietin-1 (lane 5) resulted in the inhibition of formation of the DNA fragment ladder. Thus G-CSF, daniplestim and myelopoietin-1 were able to prevent the formation of an apoptotic DNA fragment ladder.
Effects of daniplestim and myelopoietin-1 on the mitochondrial membrane potential
During the induction of apoptosis, a critical step in many cells is the release of cytochrome c from the mitochondrion and a subsequent lowering of the mitochondrial membrane potential. 1 Staining of the OCI-AML.5 cells with rhodamine 123 and then performing flow cytometric analysis (Figure 7 ) can readily identify changes in mitochondrial membrane potential. These cells express low levels of the drug resistance pumps 43 therefore this type of mitochondrial membrane potential assay can be performed on these cells.
Treatment of the OCI-AML.5 cells with no cytokine for 2 days resulted in two peaks of cells as detected by flow cytometric analysis (panel a). One peak, which comprised 78% of the cells, had a low mean rhodamine fluorescence (mean = 40) whereas the other peak, which comprised 22% of the cells, had a higher mean fluorescence (mean = 364). This second peak corresponded to the viable cells. Treatment of the cells with G-CSF for 2 days resulted in two peaks of roughly equal proportions (panel b). The peak representing dead cells with a loss of mitochondrial membrane potential contained 49% of the cells and, like the peak in the untreated cells, had a mean intensity of 39. The other rhodamine-positive peak had an intensity of 353 and contained 52% of the cells showing that addition of G-CSF resulted in a two-fold increase in viability compared to cells grown in the absence of cytokines. When the cells were treated with IL-3 (panel c), the rhodamine-positive peak was much greater than the rhodamine-negative peak and comprised 81% of the cells. When the cells were treated with daniplestim (panel d), a combination of daniplestim and G-CSF (panel e) or myelopoietin-1 (panel f), the rhodamine-positive peaks were also greater than the rhodamine-negative peaks with as much as 90 to 95% of the cells. Moreover, the rhodamine-negative peak was substantially reduced in size and had lower peak intensities (mean fluorescent intensities of approximately 10). Thus, as indicated by rhodamine 123 fluorescence, the daniplestim and myelopoietin-1 maintained the mitochondrial membrane potential better than native IL-3 or G-CSF.
Effects of daniplestim and myelopoietin-1 on the redox potential
Changes in the redox state have been associated with the induction of apoptosis since the generation of free oxygen radicals may serve as a trigger to induce apoptosis. 42 To determine whether treatment with IL-3, daniplestim or myelopoietin-1 treatments resulted in the production of intracellular peroxides, the OCI-AML.5 cells were cultured under the indicated conditions and then treated with DCFH-DA which
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Figure 8
Effects of daniplestim and myelopoietin-1 on the redox potential. The effects of the cytokines on redox potential were examined on OCI-AML.5 cells cultured in the presence of the indicated cytokines for 2 days. The cells were then stained with DCFH-DA and intracellular peroxide levels were examined by flow cytometric analysis. The mean intensities of cells in each peak are presented. These experiments were performed three times with similar results.
stains intracellular peroxides. Treatment of the cells for 2 days with no cytokines resulted in a high redox potential as reflected in a low level of binding with DCFH-DA ( Figure 8,  panel a) . In contrast, when the cells were treated with native IL-3, daniplestim or myelopoietin-1, the level of staining with DCFH-DA increased (Figure 8 , panels b, c and d) indicating a lower redox potential. Thus, the cytokine-treated cells had a lower redox potential than the untreated cells. Since the mitochondria are a major source of oxygen radical production, these results indicate that mitochondrial respiration is increased in cytokine-treated cells.
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Discussion
An important goal of hematopoietic cell therapy is the successful engraftment of stem cells, which will repopulate the stem cell compartment after myeloablative chemotherapy. In order to achieve this goal, fusion, modified and chimeric cytokines that have the ability to stimulate growth and prevent apoptosis of hematopoietic precursor cells have been developed. These cytokines may provide important tools to stimulate the repopulation of hematopoietic stem cells. However, before these cytokines are used in a therapeutic setting, more information regarding the mechanisms by which they stimulate hematopoietic cell growth and prevent apoptosis is required.
Previous studies have indicated that the modified and chimeric cytokines may exert part of their effects through enhanced signal transduction. Namely, the chimeric cytokine myelopoietin-1 induced prolonged Jak kinase activation and elevated
Figure 9
Potential signal transduction and anti-apoptotic pathways activated by myelopoietin-1. In this summary diagram, potential pathways by which myelopoietin-1 activates gene expression and prevent apoptosis are indicated. Cytokines can activate the Jak/STAT as well as the Ras/Raf/MEK/ERK and PI3K/AKT cascades. These signaling pathways can have positive and negative effects on both gene expression and apoptosis. This binding of myelopoietin-1 to the IL-3 and G-CSF receptors may induce the clustering of downstream signaling molecules into a lipid RAFT and is indicated in a yellow box. The adapter proteins (Shc, GRB2 and SOS), the GDP/GTP exchange protein Ras, the signaling kinases (Raf, MEK, ERK1,2, p90Rsk, Jak, PI3K and Akt) and the transcription factors (STAT5, CREB, NF-B and ELK) are indicated in green. The anti-apoptotic Bcl-2 family members are indicated in orange, the pro-apoptotic Bax and Bad molecules are indicated in brown. The pro-apoptotic FKHR transcription factor is indicated in black. The caspase cascade proteases, the downstream nuclease (CAD), its inhibitor (ICAD) and the 14-4-4 chaperonin proteins are indicated in black. The mitochondrial membrane potential () is indicated in black. The caspase activating protein Apaf-1 is indicated in yellow. Cytochrome C (cyto C) is indicated in magenta. In this model, the various pathways, which can be induced by cytokines, are indicated. levels of STAT DNA binding activity. 44 This increased activation of the Jak/STAT pathway may result in the augmented transcription of certain cytokine-responsive genes including the anti-apoptotic gene Bcl-X L . Some of the mechanisms by which daniplestim and myelopoietin-1 may induce cell growth and prevent apoptosis are summarized in Figure 9 .
In our studies, we have examined the ability of the daniplestim and myelopoietin-1 to prevent apoptosis. An increase in the percentage of viable cells after hematopoietic cell therapy is a desired trait, as they should serve to more effectively repopulate the progenitor cell compartment. We observed that cells treated with either myelopoietin-1 or daniplestim in the presence and absence of G-CSF were more resistant to apoptosis than cells treated with IL-3 or G-CSF alone by annexinV/PI binding and TUNEL assays. Moreover, cells treated with daniplestim and myelopoietin-1 displayed higher binding of rhodamine 123, an indicator of a higher mitochondrial membrane potential. Other investigators have validated the necessity of examining multiple apoptosis assays to confirm the induction of apoptosis. [38] [39] [40] [41] Frequently, annexin V binding, DNA laddering and TUNEL assays are used in concert to measure the extent of apoptosis in CD34 + cells. The increase in mitochondrial membrane potential is significant as it may indicate that less cytochrome c is released after treatment with daniplestim and myelopoietin-1 than after culture with either IL-3 or G-CSF. This, in turn, would suggest that the formation of the apoptosome complex of cytochrome c, Apaf-1 and caspase 9 may not occur as readily in the daniplestim or myelopoietin-1 treated cells as in the IL-3 or G-CSF-treated cells. Myelopoietin-1 treatment also resulted in a lower redox potential than cells deprived of cytokines indicating that the mitochondrial respiration rate was higher in myelopoietin-1-treated cells than in the cells treated with no cytokines. Taken together, these results suggest that a mechanism by which myelopoietin-1 stimulates growth and prevents apoptosis is by preserving the integrity and metabolic functions of the mitochondrion.
A key attribute of cytokines, such as IL-3, is their ability to prevent cell death. This is achieved via a pathway distinct from Jak-STAT signaling. It may be triggered after crosslinking of the IL-3 receptor by IL-3/daniplestim/myelopoietin-1 and induction of the PI3K/AKT anti-apoptotic cascade which results in the phosphorylation of the IK, and pro-apoptotic molecules such as Bad, FKHR, glycogen synthetase-3 (Gsk-3) and caspase-9. The phosphorylation of IK by Akt results in the activation of IK which in turn phosphorylates IB. 45 IB then undergoes ubiquitination and is targeted for degradation in the proteosomes. The nuclear localization sequences in NF-B are now exposed on NF-B and it can enter the nucleus and stimulate the expression of anti-apoptotic genes such as inhibitors of apoptosis (IAPs). 46 In contrast, phosphorylation of many pro-apoptotic proteins (eg Bad, FKHR and Gsk-3) by Akt results in their inactivation and hence prevention of apoptosis. Akt phosphorylates and inactivates FKHR preventing the induction of Fas by this mechanism. The PI3K pathway has been shown to protect certain primary CD34 + hematopoietic cells from apoptosis. 41 A key question which remains is how chimeric cytokines such as myelopoietin-1 stimulate hematopoietic cell repopulation in vivo better than the individual cytokines themselves (in this case daniplestim and G-CSF). This may be due to the formation of signaling 'RAFTs' in the cell membrane, which could include many cytokine receptors as well as their downstream signaling components. [47] [48] [49] A hypothetical RAFT is shown in the yellow box surrounding the IL-3 and G-CSF receptors in Figure 9 . Signaling 'RAFTs' are hypothesized to localize and concentrate signaling components and increase the efficiency of signal transduction. If an individual chimeric cytokine can activate more than one receptor in the signaling 'RAFT' it may increase the effectiveness of this 'RAFT' in transducing growth and anti-apoptotic signals. A single chimeric cytokine interacting with two cytokine receptors may be more effective as a result of one hit kinetics as compared to two hit kinetics. Moreover, in treatment of transplant patients, the effective doses of the cytokine may be very low even though the administered dose is relatively high, hence any increase in the effectiveness of a cytokine is predicted to have substantial beneficial effects. This may become increasing relevant in the treatment of transplant patients with respect to avoiding deleterious side-effects, ie, it would be beneficial to use low doses of a very effective cytokine to stimulate hematopoietic cell repopulation.
The chimeric cytokine myelopoietin-1 resembled IL-3 and
Leukemia not G-CSF in preventing apoptosis. This indicates that even though the G-CSF receptor is activated by myelopoietin-1, it does not exert a negative effect on the induction of apoptosis. Furthermore, daniplestim prevented apoptosis better than native IL-3. The cumulative effects of cytokines may be due to a balance of proliferative and anti-apoptotic activities. Thus, the enhanced proliferative effects of these cytokines may be due in part to their effects on the prevention of apoptosis.
